You are here: Home > articles > Shares > Bitter News for Tate & Lyle, US Inversion Legislation hits UK Pharmaceutical Shares
Bitter News for Tate & Lyle, US Inversion Legislation hits UK Pharmaceutical Shares
September 23, 2014 7:19 amVideo
Latest News
- Fed to keep policy tight for longer than markets view April 18, 2024
- Technical Analysis – BTCUSD drops to 6-week low as halving looms April 18, 2024
- Midweek Technical Look – EURUSD, US 500, WTI April 18, 2024
- Technical Analysis – AUDJPY pulls back but stays in uptrend April 18, 2024
- Forex forecast 04/18/2024: EUR/USD, USD/JPY, Oil and Bitcoin from Sebastian Seliga April 18, 2024
- Video market update for April 18, 2024 April 18, 2024
- Technical Analysis – WTI oil futures exit sideways move to the downside April 18, 2024
- Market Comment – US dollar on the back foot as nervousness lingers in equity markets April 18, 2024
- Hot forecast for EUR/USD on April 18, 2024 April 18, 2024
- EUR/USD and GBP/USD: Technical analysis on April 18 April 18, 2024
- Trading plan for GBP/USD on April 18. Simple tips for beginners April 18, 2024
- Trading plan for EUR/USD on April 18. Simple tips for beginners April 18, 2024
- The Fed and global instability: a double blow to American markets April 18, 2024
- Forecast for EUR/USD on April 18, 2024 April 18, 2024
- Forecast for GBP/USD on April 18, 2024 April 18, 2024
- Forecast for AUD/USD on April 18, 2024 April 18, 2024
- Outlook for GBP/USD on April 18. Pound was not impressed by the inflation data April 18, 2024
- Outlook for EUR/USD on April 18. Euro has fallen into a new flat April 18, 2024
- GBP/USD. Correction or trend reversal? April 18, 2024
- The FOMC will not lower rates in 2024 April 18, 2024
The S&P500 closed down by 0.8% yesterday after a drop in both existing home sales and key commodity markets weighed on the markets. Brent and WTI Crude futures fell after the Chinese Finance Minister reiterated the government’s determination not to boost economic stimulus in response to gloomy data. However, both Brent and WTI are up this morning, boosted by surprisingly positive macroeconomic data out of China this morning; the HSBC Manufacturing PMI preliminary release for September stands at 50.5 rather than the expected 50, meaning that the Manufacturing Industry is still expanding slightly. The news helped to strengthen the Shanghai Composite, with the index closing up by 0.87% this morning.
It continues to be a tough week for Tesco as the company struggles to deal with the fallout after admitting that it had overestimated profits for the first half of 2014 by around £250 million. Alan Stewart, a finance director hired by Tesco from M&S who was due to start in December, will begin his new role at the UK’s number 1 supermarket chain this week instead after an agreement between the two companies. Tesco’s share price is currently down by around 2.5% on the FTSE 100. However, the biggest loser this morning is undoubtedly Tate and Lyle on the FTSE 250, with shares currently down by around 16% after the firm issued a profit warning for the first half of 2014, apportioning part of the blame to the harsh winter conditions in the US at the beginning of the year having affected its supply chain. Back on the FTSE 100, Barclays share price is currently down by around 0.6% after the bank was fined for failing to segregate client assets from bank funds. It is the second time that Barclays has been fined for this, with the first coming back in 2011 when the FSA handing the bank a £1.1 million penalty. The FCA’s fine this time around is considerably higher, with the amount Barclays will have to pay in the region of £38 million.
Meanwhile, the US government announced measures on Monday intended to clamp down on the policy of inversion, which has allowed US companies to move their tax base offshore through purchasing foreign businesses. US companies will from now on face further restrictions designed to prevent them avoiding US taxes by restructuring themselves abroad. UK Pharmaceutical company AstraZeneca saw shares fall this morning in response to the news, with the likelihood of Pfizer returning for another takeover attempt later this year now looking more remote. Smith & Nephew, another UK medical company recently mentioned in connection with a potential merger deal, also saw its share price fall this morning, with stock currently down by around 3%.
Related Posts: